Clinical Trials - ArriVent Biopharma

Programs

FURVENT
FURMO-004
First-line Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
FURMO-002
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations

For more information about furmonertinib clinical studies:

FURMO@nullarrivent.com